Shares of Oncobiologics Inc (NASDAQ:ONS) have earned a consensus broker rating score of 3.00 (Hold) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation.

Zacks has also assigned Oncobiologics an industry rank of 90 out of 255 based on the ratings given to related companies.

Separately, ValuEngine upgraded shares of Oncobiologics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.

NASDAQ:ONS opened at $0.89 on Wednesday. The company has a debt-to-equity ratio of -0.27, a quick ratio of 0.41 and a current ratio of 0.41. Oncobiologics has a 1-year low of $0.77 and a 1-year high of $2.30.

About Oncobiologics

Oncobiologics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics in immunology and oncology disease areas. Its advanced product candidate is ONS-3010, an adalimumab biosimilar that is in a Phase 1 clinical trial, which targets the tumor necrosis factor alpha.

Further Reading: Asset Allocation Models, Which is Right For You?

Get a free copy of the Zacks research report on Oncobiologics (ONS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.